In a real-world study of 56 patients with NAFLD and Type 2 diabetes mellitus who received SGLT-2 inhibitors for 48 weeks, there were statistically significant decreases in both controlled attenuation parameter (CAP) from 312 dB/m at baseline to 280 dB/m at week 48, and liver stiffness measurement (LSM) from 9.1 kPa at baseline to 6.7 kPa at week 4811. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.